AOD-9604 research guide for Il. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
Most researchers looking for AOD-9604 in Il soon discover that local retail options are virtually absent. What this means for Il researchers is that your location matters far less than your ability to verify analytical documentation — and those verification methods are available to every researcher. A properly operating AOD-9604 supplier's COA must contain HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all traceable to your specific batch. This guide takes Il researchers through that evaluation process and explains what quality documentation for AOD-9604 should look like.
AOD-9604 Mechanisms Explained
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Il comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
AOD-9604 Purchasing Guide
Assessing AOD-9604 vendors requires starting from the COA: locate the batch-specific certificate before placing an order, not after. Endotoxin testing in the COA is critical for any injectable research use — endotoxins from gram-negative bacterial contamination can trigger severe inflammatory responses even at trace quantities. For Il researchers evaluating vendors with limited track records: a test quantity before committing to research volumes before committing to research quantities is what experienced peptide researchers consistently do. For Il researchers making a first AOD-9604 purchase: verify the vendor against this framework, begin with a small order, and check that batch numbers on your vial match the COA before use.
Order AOD-9604 — ships to Il
COA-verified · International tracking · Research grade
As a research compound, AOD-9604 has not completed the clinical trial process required for pharmaceutical approval — its safety profile is defined by animal study data and limited human studies. Lyophilised AOD-9604 should be frozen at −20°C as soon as it arrives; repeated freeze-thaw cycles of reconstituted material should be avoided by aliquoting into single-use portions. Verify the endotoxin level in your AOD-9604 batch COA before use in any in-vivo protocol — look for results reported in endotoxin units per mg or mL and confirm they fall within appropriate thresholds. The research literature on AOD-9604 should be studied thoroughly before beginning any research — study approaches, dose levels, and measured endpoints vary significantly and conclusions do not uniformly extrapolate.
Frequently Asked Questions
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
